ヒトパピローマウイルス（HPV）ワクチンの市場規模、シェア、動向分析レポート：タイプ別、疾患別、流通チャネル別、地域別、セグメント予測、2025～2030年

ヒトパピローマウイルスワクチン市場の成長と動向

Grand View Research, Inc.の最新レポートによると、ヒトパピローマウイルスワクチンの世界市場規模は、2025～2030年にかけてCAGR 8.82%を記録し、2030年までに140億3,000万米ドルに達する見込みです。HPVワクチン接種の推進における政府や国際保健機関の関与の増加は、市場成長を大きく後押ししています。例えば、2024年11月、ラオス人民民主共和国（ラオスPDR）保健省は、ユニセフ、世界保健機関（WHO）、ワクチン同盟Gaviと協力し、オーストラリア政府の支援を受けて、2024年ヒトパピローマウイルス（HPV）予防接種キャンペーンを正式に開始しました。多くの国々が、GAVI、WHO、PAHOなどの世界的組織からの資金援助を受けて、HPVワクチンを国の予防接種スケジュールに導入しています。このような協力関係により、中低所得国でのワクチンへのアクセスが拡大し、コストの障壁や物流の課題を克服するのに役立っています。

さらに、学校を拠点としたワクチン接種プログラムは、HPV予防の主要な対象である青少年層へのアプローチにおいて特に効果的でした。PAHOの回転基金や、CervavacやWalrinvaxのような新しいワクチンに対するWHOの事前承認プロセスも、利用しやすい選択肢の幅を広げています。子宮頸がん撲滅というWHOの目標達成を目指す国が増える中、HPVワクチン接種は国家戦略の柱となりつつあり、官民双方の需要を押し上げ、大きな市場機会を生み出しています。

HPV感染、関連する健康リスク、ワクチン接種の利点に関する世界の意識の高まりは、市場成長を促進する主な要因です。公衆衛生キャンペーン、ソーシャルメディアアウトリーチ、学校ベースの教育イニシアティブは、認識を変え、ワクチンの受け入れを促す上で極めて重要な役割を果たしています。オーストラリアやイギリスなど、強力な医療コミュニケーション戦略を持つ国では、HPVワクチンの接種率が際立って高く、これは一貫したエビデンスに基づく啓発活動の効果を反映しています。性別にとらわれないワクチン接種のメッセージは、特に男性における中咽頭がんや肛門がんの罹患率の増加を受けて、男性集団の受け入れも改善しています。セクシャルヘルスに対する偏見が薄れ、ワクチン接種の長期的ながん予防効果がより多くの人々に認識されるにつれ、より幅広い層の人々がワクチン接種を受けるようになっています。こうした認識向上への取り組みは、需要を増加させるだけでなく、ワクチン接種の早期化、コンプライアンス率の向上、より安定した市場成長にもつながっています。

HPV関連がん、特に子宮頸がんの世界的な有病率の増加は、HPVワクチン市場の強力な成長促進要因の一つです。世界保健機関（WHO）によると、2022年、子宮頸がんは世界で34万2,000人以上の死因となり、女性の間で4番目に多いがんとなりました。子宮頸がん患者の約95％は、主に16型と18型の高リスク型HPVの持続感染に関連しています。同様に、中咽頭がん、肛門がん、陰茎がん、膣がん、外陰がんなど、他のHPV関連がんの発生率も、特に高所得国で増加傾向にあります。例えば、米国では現在、中咽頭がんの70％以上がHPVに起因しており、この傾向は過去10年間着実に増加しています。このような疾病負担の増大により、公衆衛生上の課題としてHPVワクチン接種の役割が高まっています。診断とサーベイランスが改善し、HPV関連がんのデータがより確かなものとなるにつれ、特に青少年を対象とした広範なワクチン接種戦略の実施が急務となり、世界市場の需要が加速しています。

ヒトパピローマウイルスワクチン市場レポートハイライト

• 2024年、タイプ別では4価ワクチンが75.67%の市場シェアを占めました。これは4つの主要なHPV-6、11、16、18型に対する包括的な予防効果があるためです。これらの型は子宮頸がん患者の70%近くと性器疣贅の90%近くを引き起こすことが知られており、4価ワクチンは世界のHPV予防接種戦略において重要な要素となっています。
• 2024年、疾患別では子宮頸がん分野が市場を独占し、63.78%の売上シェアを獲得しました。子宮頸がんは、HPVに関連した悪性腫瘍の中で最も罹患率の高いもの一つであり、主にHPV16型と18型によって引き起こされ、全症例の約70%を占めています。
• 2024年、流通チャネル別では病院と小売薬局のセグメントが54.75%の最大シェアを占め、予測期間中に最も急成長すると予測されています。この動向は主に、これらのヘルスケア施設がHPVワクチン接種を希望する患者に提供するアクセス性、利便性、信頼性の高まりによるものです。
• 2024年には、北米が39.83%のシェアで世界市場を牽引し、その原動力となったのは、広範な予防接種の適用範囲、強力な公衆衛生キャンペーン、公的・私的ヘルスケアシステムの両方におけるHPVワクチンの早期導入であり、幅広い人口保護が確保されています。
• 世界のHPVワクチン市場の主な企業は、Merck & Co., Inc.、GlaxoSmithKline plc (GSK)、Serum Institute of India Pvt. Ltd.などがあります。すべての主要企業は、新製品の発売、戦略的パートナーシップの締結、新地域への進出などの戦略を通じて、世界での存在感を強めています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ヒトパピローマウイルス（HPV）ワクチン市場の変数、動向、範囲

• 市場セグメンテーションと範囲
• 市場系統の展望
  • 親市場展望
  • 関連/補助市場展望
• 市場動向と展望
• 市場力学
  • HPV関連がんの罹患率の上昇
  • 政府とNGOの予防接種プログラム
  • 意識向上と教育活動
  • ヘルスケア費の増加
  • ワクチン技術の進歩
• 市場抑制要因分析
  • ワクチンの高額な費用
  • 十分なサービスを受けていない地域での認知度の低さ
  • ポーターのファイブフォース分析
  • PESTEL分析

第4章 ヒトパピローマウイルス（HPV）ワクチン市場：タイプ別、推定・動向分析

• ヒトパピローマウイルス（HPV）ワクチン市場：タイプ変動分析
• タイプ別
• 2価
• 4価
• 9価

第5章 ヒトパピローマウイルス（HPV）ワクチン市場：疾患別、推定・動向分析

• ヒトパピローマウイルス（HPV）ワクチン市場：疾患変動分析
• 疾患別
• 子宮頸がん
• 膣がんおよび外陰がん
• 肛門がん
• 中咽頭（頭頸部）がん
• 性器イボ

第6章 ヒトパピローマウイルス（HPV）ワクチン市場：流通チャネル別、推定・動向分析

• ヒトパピローマウイルス（HPV）ワクチン市場：流通チャネル変動分析
• 流通チャネル別
• 病院・薬局
• 政府サプライヤー
• その他

第7章 ヒトパピローマウイルス（HPV）ワクチン市場：地域別、推定・動向分析

• ヒトパピローマウイルス（HPV）ワクチン市場シェア：地域別、2024年および2030年
• 地域別市場シェア分析、2024年および2030年
• 地域別市場ダッシュボード
• 世界地域市場のスナップショット
• 市場規模、予測動向分析、2018～2030年
• 北米
  • 北米のヒトパピローマウイルス（HPV）ワクチン市場、2018～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 欧州のヒトパピローマウイルス（HPV）ワクチン市場、2018～2030年
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • アジア太平洋地域のヒトパピローマウイルス（HPV）ワクチン市場、2018～2030年
  • 日本
  • 中国
  • インド
  • オーストラリア
  • タイ
  • 韓国
• 南米
  • 南米のヒトパピローマウイルス（HPV）ワクチン市場、2018～2030年
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカのヒトパピローマウイルス（HPV）ワクチン市場、2018～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業分類
• 戦略マッピング
• 企業市場シェア分析、2024年
• 企業プロファイル
  • Merck &Co., Inc.
  • GlaxoSmithKline plc（GSK）
  • Serum Institute of India Pvt. Ltd.
  • Sanofi Pasteur SA
  • Pfizer Inc.
  • Inovio Pharmaceuticals Inc.
  • Walvax Biotechnology Co., Ltd.
  • Bharat Biotech International Ltd.
  • Johnson &Johnson Services, Inc.
  • Moderna, Inc.
  • Gilead Sciences, Inc.

List of Table

• Table 1 List of abbreviations
• Table 2 Global Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 3 Global Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 4 Global Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 5 Global Human Papillomavirus (HPV) Vaccines Market, by Region, 2018 - 2030 (USD Million)
• Table 6 North America Human Papillomavirus (HPV) Vaccines Market, by Country, 2018 - 2030 (USD Million)
• Table 7 North America Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 8 North America Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 9 North America Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 10 U.S. Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 11 U.S. Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 12 U.S. Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 13 Canada Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 14 Canada Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 15 Canada Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 16 Mexico Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 17 Mexico Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 18 Mexico Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 19 Europe Human Papillomavirus (HPV) Vaccines Market, by Country, 2018 - 2030 (USD Million)
• Table 20 Europe Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 21 Europe America Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 22 Europe America Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 23 UK Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 24 UK Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 25 UK Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 26 Germany Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 27 Germany Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 28 Germany Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 29 France Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 30 France Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 31 France Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 32 Italy Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 33 Italy Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 34 Italy Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 35 Spain Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 36 Spain Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 37 Spain Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 38 Denmark Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 39 Denmark Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 40 Denmark Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 41 Sweden Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 42 Sweden Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 43 Sweden Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 44 Norway Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 45 Norway Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 46 Norway Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 47 Asia Pacific Human Papillomavirus (HPV) Vaccines Market, by Country, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 51 Japan Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 52 Japan Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 53 Japan Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 54 China Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 55 China Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 56 China Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 57 India Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 58 India Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 59 India Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 60 Australia Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 61 Australia Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 62 Australia Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 63 Thailand Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 64 Thailand Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 65 Thailand Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 66 South Korea Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 67 South Korea Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 68 South Korea Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 69 Latin America Human Papillomavirus (HPV) Vaccines Market, by Country, 2018 - 2030 (USD Million)
• Table 70 Latin America Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 71 Latin America Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 72 Latin America Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 73 Brazil Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 74 Brazil Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 75 Brazil Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 76 Argentina Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 77 Argentina Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 78 Argentina Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 79 Middle East & Africa Human Papillomavirus (HPV) Vaccines Market, by Country, 2018 - 2030 (USD Million)
• Table 80 Middle East & Africa Human Papillomavirus (HPV) Vaccines Market, by type, 2018 - 2030 (USD Million)
• Table 81 Middle East & Africa Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 83 South Africa Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 84 South Africa Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 85 South Africa Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 86 Saudi Arabia Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 88 audi Arabia Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 89 UAE Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 90 UAE Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 91 UAE Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 92 Kuwait Human Papillomavirus (HPV) Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 93 Kuwait Human Papillomavirus (HPV) Vaccines Market, by Disease, 2018 - 2030 (USD Million)
• Table 94 Kuwait Human Papillomavirus (HPV) Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 Market formulation & validation
• Fig. 7 Human Papillomavirus (HPV) Vaccines Market segmentation
• Fig. 8 Market snapshot, 2024
• Fig. 9 Market trends & outlook
• Fig. 10 Market driver relevance analysis (current & future impact)
• Fig. 11 Market restraint relevance analysis (current & future impact)
• Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
• Fig. 13 Porter's five forces analysis
• Fig. 14 Human papillomavirus (HPV) vaccines market: Type movement analysis
• Fig. 15 Human papillomavirus (HPV) vaccines market: Type outlook and key takeaways
• Fig. 16 Bivalent market estimates and forecast, 2018 - 2030
• Fig. 17 Quadrivalent market estimates and forecast, 2018 - 2030
• Fig. 18 Nonavalent market estimates and forecast, 2018 - 2030
• Fig. 19 Human papillomavirus (HPV) vaccines market: Disease movement analysis
• Fig. 20 Human papillomavirus (HPV) vaccines market: Disease outlook and key takeaways
• Fig. 21 Cervical Cancer market estimates and forecast, 2018 - 2030
• Fig. 22 Vaginal and Vulvar Cancers market estimates and forecast, 2018 - 2030
• Fig. 23 Anal Cancer market estimates and forecast, 2018 - 2030
• Fig. 24 Oropharyngeal (Head and Neck) Cancers market estimates and forecast, 2018 - 2030
• Fig. 25 Genital Warts market estimates and forecast, 2018 - 2030
• Fig. 26 Human papillomavirus (HPV) vaccines market: Distribution channel movement analysis
• Fig. 27 Human papillomavirus (HPV) vaccines market: Distribution channel outlook and key takeaways
• Fig. 28 Hospitals and Retail Pharmacies market estimates and forecast, 2018 - 2030
• Fig. 29 Government Suppliers market estimates and forecast, 2018 - 2030
• Fig. 30 Others market estimates and forecast, 2018 - 2030
• Fig. 31 Regional outlook, 2024 & 2030
• Fig. 32 Global Human Papillomavirus (HPV) Vaccines Market: Region movement analysis
• Fig. 33 North America Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 34 U.S. Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 35 Canada Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 36 Mexico Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 37 Europe Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 38 Germany Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 39 UK Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 40 France Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 41 Italy Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 42 Spain Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 43 Denmark Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 44 Sweden Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 45 Norway Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 46 Asia Pacific Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 47 Japan Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 48 China Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 49 India Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 50 Australia Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 51 South Korea Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 52 Thailand Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 53 Latin America Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 54 Brazil Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 55 Argentina Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 56 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 57 South Africa Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 58 Saudi Arabia Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 59 UAE Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 60 Kuwait Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)

Human Papillomavirus Vaccines Market Growth & Trends:

The global Human Papillomavirus vaccines market size is expected to reach USD 14.03 billion by 2030, registering a CAGR of 8.82% from 2025 to 2030, according to a new report by Grand View Research, Inc., driven by several key factors. The increasing involvement of governments and international health organizations in promoting HPV vaccination is significantly propelling market growth. For instance, in November 2024, the Ministry of Health of the Lao People's Democratic Republic (Lao PDR), in collaboration with UNICEF, the World Health Organization (WHO), and Gavi, the Vaccine Alliance-with support from the Government of Australia-officially launched the 2024 Human Papillomavirus (HPV) immunization campaign. Many countries have introduced HPV vaccines into their national immunization schedules, often with funding support from global organizations such as GAVI, WHO, and PAHO. These collaborations have expanded access to vaccines in low- and middle-income countries, helping overcome cost barriers and logistical challenges.

In addition, school-based vaccination programs have been particularly effective in reaching adolescent populations, which are the primary target for HPV prevention. The Pan American Health Organization's revolving fund and WHO's prequalification process for new vaccines like Cervavac and Walrinvax have also broadened the landscape of accessible options. As countries increasingly aim to meet the WHO's goal of eliminating cervical cancer, HPV vaccination is becoming a central pillar in their national strategies, boosting both public and private sector demand and creating significant market opportunities.

Increased global awareness regarding HPV transmission, associated health risks, and the benefits of vaccination is a major factor driving market growth. Public health campaigns, social media outreach, and school-based education initiatives have played a pivotal role in changing perceptions and encouraging vaccine acceptance. In countries with robust healthcare communication strategies, such as Australia and the UK, HPV vaccine uptake is notably high, reflecting the impact of consistent, evidence-based awareness efforts. Gender-neutral vaccination messaging has also improved acceptance among male populations, particularly in response to the growing incidence of oropharyngeal and anal cancers in men. As stigma around sexual health diminishes and more people recognize the long-term cancer prevention benefits of vaccination, broader demographic groups are being reached. These awareness initiatives are not only increasing demand but are also leading to earlier vaccination, higher compliance rates, and more consistent market growth.

The increasing global prevalence of HPV-related cancers, particularly cervical cancer, is one of the strongest growth drivers of the HPV vaccines market. According to the World Health Organization (WHO), in 2022, cervical cancer was responsible for over 342,000 deaths worldwide, making it the fourth most common cancer among women. Approximately 95% of cervical cancer cases are linked to persistent infection with high-risk HPV types, primarily types 16 and 18. Similarly, the incidence of other HPV-associated cancers-such as oropharyngeal, anal, penile, vaginal, and vulvar cancers-is on the rise, especially in high-income countries. For example, HPV is now responsible for over 70% of oropharyngeal cancers in the United States, a trend that has been steadily increasing over the past decade. This growing disease burden has elevated the role of HPV vaccination in public health agendas. With improved diagnostics and surveillance, and as HPV-related cancer data becomes more robust, the urgency to implement broad vaccination strategies, particularly for adolescents, is accelerating global market demand.

Human Papillomavirus Vaccines Market Report Highlights:

• In 2024, the quadrivalent segment held the largest market share of 75.67%, attributed to its comprehensive protection against four major HPV types-6, 11, 16, and 18. These strains are known to cause nearly 70% of cervical cancer cases and about 90% of genital warts, making the quadrivalent vaccine a key component in HPV immunization strategies worldwide.
• In 2024, the cervical cancer segment dominated the market, capturing a revenue share of 63.78%, driven by increased awareness and strong preventive measures. Cervical cancer is among the most prevalent HPV-related malignancies, primarily caused by HPV types 16 and 18, which are responsible for approximately 70% of all cases.
• In 2024, the hospitals and retail pharmacies segment held the largest revenue share of 54.75% and is projected to experience the fastest growth during the forecast period. This trend is primarily driven by the growing accessibility, convenience, and reliability that these healthcare facilities offer to patients seeking HPV vaccination.
• In 2024, North America led the global market with a share of 39.83%, fueled by extensive immunization coverage, robust public health campaigns, and early adoption of HPV vaccines across both public and private healthcare systems, ensuring broad population protection.
• The global HPV vaccines market is led by several major companies, including Merck & Co., Inc., GlaxoSmithKline plc (GSK), Serum Institute of India Pvt. Ltd., among others. All key companies are strengthening their worldwide presence through strategies like launching new products, forging strategic partnerships, and expanding into new geographic regions.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Disease
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Disease outlook
  • 2.2.3. Distribution channel outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Human Papillomavirus (HPV) Vaccines Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends and Outlook
• 3.4. Market Dynamics
  • 3.4.1. Rising prevalence of HPV-related cancers
  • 3.4.2. Government and NGO immunization programs
  • 3.4.3. Growing Awareness and education initiatives
  • 3.4.4. Increase in healthcare expenditure
  • 3.4.5. Advancements in vaccine technology
• 3.5. Market Restraint Analysis
  • 3.5.1. High vaccine costs
  • 3.5.2. Limited Awareness in Underserved Regions
  • 3.5.3. Porter's Five Forces Analysis
  • 3.5.4. PESTEL Analysis

Chapter 4. Human Papillomavirus (HPV) Vaccines Market: Type Estimates & Trend Analysis

• 4.1. Human Papillomavirus (HPV) Vaccines Market: Type Movement Analysis
• 4.2. Human Papillomavirus (HPV) Vaccines Market Estimates and Forecast, by Type
• 4.3. Bivalent
  • 4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.4. Quadrivalent
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Nonavalent
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Human Papillomavirus (HPV) Vaccines Market: Disease Estimates & Trend Analysis

• 5.1. Human Papillomavirus (HPV) Vaccines Market: Disease Movement Analysis
• 5.2. Human Papillomavirus (HPV) Vaccines Market Estimates and Forecast, by Disease
• 5.3. Cervical Cancer
  • 5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.4. Vaginal and Vulvar Cancers
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Anal Cancer
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Oropharyngeal (Head and Neck) Cancers
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Genital Warts
  • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Human Papillomavirus (HPV) Vaccines Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Human Papillomavirus (HPV) Vaccines Market: Distribution Movement Analysis
• 6.2. Human Papillomavirus (HPV) Vaccines Market Estimates and Forecast, by Distribution Channel
• 6.3. Hospitals and Retail Pharmacies
  • 6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Government Suppliers
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Others
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Human Papillomavirus (HPV) Vaccines Market: Regional Estimates & Trend Analysis

• 7.1. Human Papillomavirus (HPV) Vaccines Market Share By Region, 2024 & 2030
• 7.2. Regional Market Share Analysis, 2024 & 2030
• 7.3. Regional Market Dashboard
• 7.4. Global Regional Market Snapshot
• 7.5. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.6. North America
  • 7.6.1. North America Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.6.2. U.S.
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. U.S. Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.6.3. Canada
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Canada Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.6.4. Mexico
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Mexico Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• 7.7. Europe
  • 7.7.1. Europe Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.2. UK
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. UK Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.3. Germany
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Germany Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.4. France
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. France Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.5. Italy
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Italy Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.6. Spain
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory Framework
    • 7.7.6.4. Spain Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.7. Denmark
    • 7.7.7.1. Key Country Dynamics
    • 7.7.7.2. Competitive Scenario
    • 7.7.7.3. Regulatory Framework
    • 7.7.7.4. Denmark Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.8. Sweden
    • 7.7.8.1. Key Country Dynamics
    • 7.7.8.2. Competitive Scenario
    • 7.7.8.3. Regulatory Framework
    • 7.7.8.4. Sweden Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.9. Norway
    • 7.7.9.1. Key Country Dynamics
    • 7.7.9.2. Competitive Scenario
    • 7.7.9.3. Regulatory Framework
    • 7.7.9.4. Norway Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• 7.8. Asia Pacific
  • 7.8.1. Asia Pacific Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.8.2. Japan
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Japan Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.8.3. China
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. China Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.8.4. India
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. India Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.8.5. Australia
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Australia Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.8.6. Thailand
    • 7.8.6.1. Key Country Dynamics
    • 7.8.6.2. Competitive Scenario
    • 7.8.6.3. Regulatory Framework
    • 7.8.6.4. Thailand Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.8.7. South Korea
    • 7.8.7.1. Key Country Dynamics
    • 7.8.7.2. Competitive Scenario
    • 7.8.7.3. Regulatory Framework
    • 7.8.7.4. South Korea Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• 7.9. Latin America
  • 7.9.1. Latin America Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.9.2. Brazil
    • 7.9.2.1. Key Country Dynamics
    • 7.9.2.2. Competitive Scenario
    • 7.9.2.3. Regulatory Framework
    • 7.9.2.4. Brazil Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.9.3. Argentina
    • 7.9.3.1. Key Country Dynamics
    • 7.9.3.2. Competitive Scenario
    • 7.9.3.3. Regulatory Framework
    • 7.9.3.4. Argentina Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• 7.10. MEA
  • 7.10.1. MEA Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.10.2. South Africa
    • 7.10.2.1. Key Country Dynamics
    • 7.10.2.2. Competitive Scenario
    • 7.10.2.3. Regulatory Framework
    • 7.10.2.4. South Africa Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.10.3. Saudi Arabia
    • 7.10.3.1. Key Country Dynamics
    • 7.10.3.2. Competitive Scenario
    • 7.10.3.3. Regulatory Framework
    • 7.10.3.4. Saudi Arabia Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.10.4. UAE
    • 7.10.4.1. Key Country Dynamics
    • 7.10.4.2. Competitive Scenario
    • 7.10.4.3. Regulatory Framework
    • 7.10.4.4. UAE Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.10.5. Kuwait
    • 7.10.5.1. Key Country Dynamics
    • 7.10.5.2. Competitive Scenario
    • 7.10.5.3. Regulatory Framework
    • 7.10.5.4. Kuwait Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company Categorization
• 8.3. Strategy Mapping
• 8.4. Company Market Share Analysis, 2024
• 8.5. Company Profiles
  • 8.5.1. Merck & Co., Inc.
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. GlaxoSmithKline plc (GSK)
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Serum Institute of India Pvt. Ltd.
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Sanofi Pasteur SA
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Pfizer Inc.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Inovio Pharmaceuticals Inc.
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Walvax Biotechnology Co., Ltd.
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Bharat Biotech International Ltd.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Johnson & Johnson Services, Inc.
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Moderna, Inc.
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives
  • 8.5.11. Gilead Sciences, Inc.
    • 8.5.11.1. Overview
    • 8.5.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic Initiatives